TY - JOUR
T1 - Prevalence of Open-Angle Glaucoma in Greece
T2 - The Thessaloniki Eye Study
AU - Topouzis, Fotis
AU - Wilson, M. Roy
AU - Harris, Alon
AU - Anastasopoulos, Eleftherios
AU - Yu, Fei
AU - Mavroudis, Leonidas
AU - Pappas, Theofanis
AU - Koskosas, Archimidis
AU - Coleman, Anne L.
N1 - Funding Information:
This study was supported by unrestricted Grants from the International Glaucoma Association, London, United Kingdom; the UCLA Center for Eye Epidemiology, Los Angeles, California; the Health Future Foundation, Creighton University, Omaha, Nebraska; Texas Tech University Health Sciences Center, Lubbock, Texas; Pfizer, Inc, New York, New York; Glaucoma Research & Education Foundation, Indianapolis, Indianapolis; Pharmacia Hellas, Athens, Greece; Novartis Hellas, Athens, Greece; the 03ED 938 research project, implemented within the framework of the “Reinforcement Programme of Human Research Manpower” (PENED) and co-financed by National and Community Funds (25% from the Greek Ministry of Development-General Secretariat of Research and Technology and 75% from E.U.-European Social Fund). The authors indicate no financial conflict of interest. Drs Topouzis and Wilson serve on the Glaucoma Advisory Board for Pfizer Ophthalmics. Dr Topouzis serves on the Glaucoma Advisory Board for Alcon. Dr Harris received research grant support from Merck and Co, Inc. Dr Coleman received an honorarium for lecturing from Pfizer, Inc. Involved in design and conduct of study (F.T., M.R.W., A.H., A.C.); collection (F.T., E.A., L.M., T.P., A.K.), management (F.T.), and analysis and interpretation of the data (F.T., M.R.W., A.H., F.Y., E.A., L.M., T.P., A.K., A.C.); preparation of the manuscript (F.T., M.R.W.); and review and approval of the manuscript (F.T., M.R.W., A.H., F.Y., E.A., L.M., T.P., A.K., A.C.). The study was approved by the Aristotle University Medical School Ethics Committee. The Institutional Review Board of the University of California, Los Angeles, approved the plans for data analyses. All study procedures adhered to the principles outlined in the Declaration of Helsinki for research involving human subjects and all participants gave written informed consent before their participation.
PY - 2007/10
Y1 - 2007/10
N2 - Purpose: To estimate the prevalence of open-angle glaucoma (OAG) in a population-based sample of subjects 60 years of age or older in Thessaloniki, Greece. Design: Cross-sectional population-based study. Methods: Subjects randomly identified from municipality registers in Thessaloniki underwent a complete ophthalmologic examination. Glaucoma was defined in two ways. Definition 1 was based on the presence of both glaucomatous optic disk and confirmed glaucomatous visual field defect. Subjects also were classified as having glaucoma when the clinical judgment was strongly in favor of the presence of glaucoma even though the strict criteria were not fulfilled (definition 2). Results: Of the 3,617 eligible subjects, 2,554 (71%) participated. The prevalence of OAG was 3.8% and 5.5% by definitions 1 and 2, respectively. The prevalence of primary OAG was 2.7% and 3.8% by definitions 1 and 2, respectively, and the prevalence of pseudoexfoliation glaucoma (PEXG) was 1.1% and 1.7% by definitions 1 and 2, respectively. Pseudoexfoliation was present in 11.9% of participants, whereas 15.2% among those with pseudoexfoliation had PEXG. Conclusions: The prevalence of OAG in the Thessaloniki Eye Study (TES) is similar or slightly higher compared with other population-based studies in White persons. The overall slightly higher prevalence of OAG in the TES compared with other studies may be attributed to the high prevalence of PEXG in the TES.
AB - Purpose: To estimate the prevalence of open-angle glaucoma (OAG) in a population-based sample of subjects 60 years of age or older in Thessaloniki, Greece. Design: Cross-sectional population-based study. Methods: Subjects randomly identified from municipality registers in Thessaloniki underwent a complete ophthalmologic examination. Glaucoma was defined in two ways. Definition 1 was based on the presence of both glaucomatous optic disk and confirmed glaucomatous visual field defect. Subjects also were classified as having glaucoma when the clinical judgment was strongly in favor of the presence of glaucoma even though the strict criteria were not fulfilled (definition 2). Results: Of the 3,617 eligible subjects, 2,554 (71%) participated. The prevalence of OAG was 3.8% and 5.5% by definitions 1 and 2, respectively. The prevalence of primary OAG was 2.7% and 3.8% by definitions 1 and 2, respectively, and the prevalence of pseudoexfoliation glaucoma (PEXG) was 1.1% and 1.7% by definitions 1 and 2, respectively. Pseudoexfoliation was present in 11.9% of participants, whereas 15.2% among those with pseudoexfoliation had PEXG. Conclusions: The prevalence of OAG in the Thessaloniki Eye Study (TES) is similar or slightly higher compared with other population-based studies in White persons. The overall slightly higher prevalence of OAG in the TES compared with other studies may be attributed to the high prevalence of PEXG in the TES.
UR - http://www.scopus.com/inward/record.url?scp=34548750457&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2007.06.029
DO - 10.1016/j.ajo.2007.06.029
M3 - Article
C2 - 17893012
AN - SCOPUS:34548750457
SN - 0002-9394
VL - 144
SP - 511-519.e1
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
IS - 4
ER -